ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 102 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2016. The put-call ratio across all filers is 0.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $224,000 | +0.9% | 4,874 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $222,000 | +31.4% | 4,999 | +16.1% | 0.00% | +50.0% |
| Q2 2018 | $169,000 | -45.7% | 4,304 | 0.0% | 0.00% | -60.0% |
| Q1 2018 | $311,000 | +6.5% | 4,304 | -2.9% | 0.01% | +25.0% |
| Q4 2017 | $292,000 | +16.3% | 4,433 | -11.6% | 0.00% | 0.0% |
| Q3 2017 | $251,000 | +27.4% | 5,012 | +18.0% | 0.00% | +33.3% |
| Q2 2017 | $197,000 | +21.6% | 4,247 | -7.7% | 0.00% | 0.0% |
| Q1 2017 | $162,000 | -38.4% | 4,600 | -75.8% | 0.00% | -40.0% |
| Q3 2016 | $263,000 | +39.9% | 19,000 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $188,000 | -41.4% | 19,000 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $321,000 | -24.1% | 19,000 | 0.0% | 0.01% | -14.3% |
| Q4 2015 | $423,000 | +122.6% | 19,000 | +136.3% | 0.01% | +133.3% |
| Q3 2015 | $190,000 | -85.3% | 8,040 | -49.1% | 0.00% | -66.7% |
| Q2 2015 | $1,292,000 | – | 15,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $33,967,000 | 11.67% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $20,644,000 | 0.58% |
| Bellevue Group AG | 4,519,164 | $54,455,000 | 0.55% |
| Rhenman & Partners Asset Management AB | 622,267 | $7,498,000 | 0.53% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 47,534 | $573,000 | 0.21% |
| WASATCH ADVISORS LP | 3,274,360 | $39,456,000 | 0.16% |
| EMC Capital Management | 27,566 | $246,000 | 0.14% |
| PDT Partners, LLC | 120,828 | $1,456,000 | 0.10% |
| Virtus ETF Advisers LLC | 17,773 | $214,000 | 0.09% |
| Pinz Capital Management, LP | 15,300 | $184,000 | 0.08% |